Integra LifeSciences (IART)
(Real Time Quote from BATS)
$29.32 USD
+0.22 (0.74%)
Updated Apr 23, 2024 10:04 AM ET
3-Hold of 5 3
A Value D Growth A Momentum A VGM
Integra LifeSciences (IART) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$44.80 | $57.00 | $37.00 | 54.59% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Integra LifeSciences comes to $44.80. The forecasts range from a low of $37.00 to a high of $57.00. The average price target represents an increase of 54.59% from the last closing price of $28.98.
Analyst Price Targets (10)
Broker Rating
Integra LifeSciences currently has an average brokerage recommendation (ABR) of 2.56 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 2.75 a month ago based on 13 recommendations.
Of the 12 recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 33.33% and 8.33% of all recommendations. A month ago, Strong Buy made up 30.77%, while Buy represented 7.69%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 4 | 5 | 4 | 4 | 4 |
Sell | 2 | 2 | 2 | 2 | 2 |
Strong Sell | 1 | 1 | 2 | 2 | 2 |
ABR | 2.56 | 2.59 | 2.75 | 2.75 | 2.75 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/29/2024 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
2/16/2024 | Not Identified | Not Identified | Hold | Hold |
2/2/2024 | Truist Securities | Richard Newitter | Hold | Hold |
1/2/2024 | BTIG | Ryan Zimmerman | Not Available | Hold |
11/14/2023 | C.L. King & Associates | Kristen M Stewart | Not Available | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.56 |
ABR (Last week) | 2.59 |
# of Recs in ABR | 12 |
Average Target Price | $44.80 |
LT Growth Rate | 10.40% |
Industry | Medical - Instruments |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | 0.55 |